Literature DB >> 17115387

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Christopher G Goetz1, Stanley Fahn, Pablo Martinez-Martin, Werner Poewe, Cristina Sampaio, Glenn T Stebbins, Matthew B Stern, Barbara C Tilley, Richard Dodel, Bruno Dubois, Robert Holloway, Joseph Jankovic, Jaime Kulisevsky, Anthony E Lang, Andrew Lees, Sue Leurgans, Peter A LeWitt, David Nyenhuis, C Warren Olanow, Olivier Rascol, Anette Schrag, Jeanne A Teresi, Jacobus J Van Hilten, Nancy LaPelle.   

Abstract

This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS-UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1-day face-to-face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS-UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS-UPDRS in order to increase uniform usage. Multiple language editions are planned. A three-part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS-UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. Copyright 2006 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17115387     DOI: 10.1002/mds.21198

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  381 in total

1.  Energy cost of spontaneous walking in Parkinson's disease patients.

Authors:  Martina A Maggioni; Arsenio Veicsteinas; Susanna Rampichini; Emiliano Cè; Raffaello Nemni; Giulio Riboldazzi; Giampiero Merati
Journal:  Neurol Sci       Date:  2011-11-01       Impact factor: 3.307

2.  Health-related quality of life as an outcome variable in Parkinson's disease.

Authors:  Pablo Martinez-Martin; Mónica M Kurtis
Journal:  Ther Adv Neurol Disord       Date:  2012-03       Impact factor: 6.570

3.  Generalized motor inhibitory deficit in Parkinson's disease patients who freeze.

Authors:  Patrick G Bissett; Gordon D Logan; Nelleke C van Wouwe; Christopher M Tolleson; Fenna T Phibbs; Daniel O Claassen; Scott A Wylie
Journal:  J Neural Transm (Vienna)       Date:  2015-09-09       Impact factor: 3.575

4.  Alleviating Freezing of Gait using phase-dependent tactile biofeedback.

Authors:  Will Harrington; Andrew Greenberg; Edward King; James McNames; Lars Holmstrom; Fay B Horak; Martina Mancini
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2016-08

5.  Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Authors:  Neha Shah; Kirk A Frey; Martijn L T M Müller; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

6.  Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data.

Authors:  Stefano Ferrea; Stefan J Groiss; Saskia Elben; Christian J Hartmann; Steve B Dunnett; Anne Rosser; Carsten Saft; Alfons Schnitzler; Jan Vesper; Lars Wojtecki
Journal:  J Neurol       Date:  2018-05-03       Impact factor: 4.849

7.  Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes.

Authors:  Talia Herman; Aner Weiss; Marina Brozgol; Adi Wilf-Yarkoni; Nir Giladi; Jeffrey M Hausdorff
Journal:  J Neural Transm (Vienna)       Date:  2014-12-10       Impact factor: 3.575

8.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

9.  Initial cognitive decline is associated with cortical thinning in early Parkinson disease.

Authors:  Joana B Pereira; Per Svenningsson; Daniel Weintraub; Kolbjørn Brønnick; Alexander Lebedev; Eric Westman; Dag Aarsland
Journal:  Neurology       Date:  2014-05-07       Impact factor: 9.910

10.  Gender differences in cholinergic and dopaminergic deficits in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  J Neural Transm (Vienna)       Date:  2013-03-27       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.